Tag:

Merck

Latest Headlines

Latest Headlines

Merck bags FDA approval for its grass pollen pill Grastek

Merck picked up an expected FDA approval for the first of three immunotherapies in its allergy pipeline, gearing up to launch a grass pollen-fighting treatment with hopes of cracking a market dominated by injections.

AbbVie angles for hep C spotlight as Merck shoulders to the front

While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data from latecomer Merck have analysts relegating the Illinois company to third place despite some excellent late-stage results.

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.

UPDATED: Watch out, Gilead. Merck is mounting a hep C combo comeback

Merck may be late to the blockbuster party with its new hepatitis C drugs, but the pharma giant is moving fast with a top contender boasting high cure rates.

Merck led a $12M round for AdvanDx and its tests for tough hospital infections

Merck's venture capital arm is the lead investor in a $12 million financing round for promising molecular diagnostic outfit AdvanDx. Their target: hospital-acquired infections that are increasingly producing drug-resistant strains.

Merck vaccine plant taps R&D's Big Data platform to solve yield conundrum

Having invested in data analytics platforms in recent years, pharma R&D labs are working to develop the drugs that will justify their spending. But the experience of Merck suggests the costs can be spread across the business, with manufacturing teams finding the data analytics tools as useful as their peers in R&D do.

Merck and Ferring team up on anti-bleeding drug for the developing world

Alongside Swiss drugmaker Ferring and the World Health Organization, Merck is embarking on a multinational effort to develop an easily transportable treatment for excessive bleeding, hoping to curb global rates of postpartum hemorrhage among the world's poorest mothers.

Stallergenes beats Merck to market as FDA OKs its allergy pill

France's Stallergenes won FDA approval to market the U.S.'s first oral immunotherapy for grass allergies, giving it a head start on rival Merck, which expects to launch a similar product this year.

Merck, GlaxoSmithKline halt copay help for Obamacare patients

Merck and GlaxoSmithKline have nixed their copay assistance for Obamacare patients. The two companies say they fear subsidizing patients' drug purchases will run afoul of federal anti-kickbacks law. But many other top drugmakers- including Novartis, Sanofi and Eli Lilly--will keep their copay cards and discounts, at least for now.

Merck snags rights to NanoBio's adjuvant vaccine tech

After collaborating with the University of Michigan-spinout NanoBio over the past three years, Merck has signed off on a new licensing pact for the biotech's nanoemulsion adjuvant technology.